John Lewicki
Chief Tech/Sci/R&D Officer chez MEREO BIOPHARMA GROUP PLC
Fortune : 2 402 $ au 31/03/2024
Profil
John A.
Lewicki is currently the Chief Scientific Officer at Mereo BioPharma Group Plc since 2020.
Prior to this, he worked at OncoMed Pharmaceuticals, Inc. as the President, Chief Executive Officer & Director from 2018 to 2019.
He also worked at Scios, Inc. as a Principal from 1983 to 2000.
Dr. Lewicki holds a doctorate degree from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/01/2024 | 3 640 ( 0,00% ) | 2 402 $ | 31/03/2024 |
Postes actifs de John Lewicki
| Sociétés | Poste | Début |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Chief Tech/Sci/R&D Officer | 01/07/2020 |
Anciens postes connus de John Lewicki
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOMED PHARMACEUTICALS INC | Chief Executive Officer | 23/04/2019 |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Chief Tech/Sci/R&D Officer | - |
Formation de John Lewicki
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
